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The effect of serum angiotensin II and angiotensin II type 1 receptor gene 




Renin angiotensin system (RAS) has been 
considered one of the probable pathophysiologic 
mechanisms involved in SLE progression. 
However, the contribution of the RAS in SLE 
patients to the development of renal disease is less 
clear.1  
Angiotensin II (Ang II) is the primary effector 
molecule of the RAS. It is an octapeptide that is 
produced both systemically and locally in various 
tissues, including the heart and blood vessel walls.2 
Moreover, Ang II has the ability to augment and 
perpetuate immune responses in several tissues and 
acts as strong candidate for the perpetuation of 
visceral damage, vascular autoimmunity and 
nephritis in SLE.3  
There are two well-described subtypes of Ang 
II receptors, designated Ang II type 1 receptor 
(AT1) and Ang II type 2 receptor (AT2), both of 
which have a high affinity for Ang II.4 The Ang 
receptors are a class of G protein-coupled receptors 
with Ang II as their ligands.5 Most of the known 
physiological effects of Ang II are mediated by 
AT1 receptors, which are widely distributed in all 
organs, including liver, adrenals, brain, lung, 
kidney, heart, and vasculature.6  
Ang II contributes to the recruitment of 
infiltrating cells into the kidney and causes the 
adhesion of circulating cells to endothelial and 
mesangial cells, and the migration of inflammatory 
cells into the kidney. This process is mediated by 
upregulation of adhesion molecules, cytokines and 
chemokines such as vascular cell adhesion 
molecule-1 (VCAM-1), intercellular adhesion 
molecule-1 (ICAM-1), interleukin-6 (IL-6) and 
monocyte chemoattractant protein-1 (MCP-1).7   
Based on the action of renal AT1 receptors to 
induce kidney damage in autoimmune nephritis, 
blockade of the RAS with  angiotensin converting 
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enzyme inhibitors (ACEIs) or  angiotensin receptor 
blockers (ARBs) may be useful in protecting the 
kidney in patients with lupus or other autoimmune 
disorders.8  
With this as a background, we aimed in this 
study to measure serum Ang II and the frequency of 
AT1 receptor gene polymorphism A1166C (CC 
genotype) among a group of Egyptian children with 
lupus nephritis (LN). The relationship of serum 
Ang II   and AT1 receptor gene polymorphism with 
clinical and laboratory markers of lupus nephritis 
was fully elucidated.   
 
METHODS 
Study design and population: 
This is a case-control cross sectional study which 
included 24 patients with   pediatric SLE (pSLE) 
fulfilling at least four of the revised American 
College of Rheumatology "ACR" classification 
criteria for SLE. 9 The study was approved by the 
Ethical Committee of the Department of Pediatrics, 
Ain Shams University, Cairo, Egypt. An informed 
consent was obtained from the parents or care-
givers of the studied groups prior to enrollment. 
 
SLE patients group:  
They were 20 (83.3 %) females and 4 (16.7 %) 
males. Their ages ranged between 5 and 18 years 
with a mean ± SD of 13.9 ± 3.5 years.  All patients 
had LN (biopsy –proven) classified according to the 
revised classification of WHO criteria of LN. 10    
Ten (41.7 %) patients had LN class II, 13 (52%) 
had LN class III and IV and 1 (4%) patient had LN 
class V. 
Hypertension was diagnosed according to the 
percentiles of blood pressure for age in pediatrics. 11 
Eight (33.3 %) patients were hypertensive and 16 
(66.7%) were normotensive. 
Inclusion criteria: 
- Age at enrolment younger than 18 years. 
- Biopsy proven lupus nephritis according to 
revised classification of WHO criteria of lupus 
nephritis for patients with pSLE.    
Exclusion criteria: 
- Patients receiving angiotensin converting enzyme 
inhibitors (ACEIs) or angiotensin receptor 
blockers (ARBs) as they interfere with Ang II 
production and action as well as with 24-hours 
urinary protein measurement. 
 
Control group: 
It included 24 age and sex-matched healthy 
children. They were 18 (75%) females and 6 (25%) 
males. Their ages ranged between 5 and 16 years 
with a mean ± SD of 12.4 ± 3.4 years.  
Study measurements: 
Clinical evaluation: 
Detailed history taking with special emphasis on 
age at onset of SLE, duration and presentation of 
LN.  Cumulative doses of steroids, azathioprine and 
cyclophosphamide were calculated. Detailed 
antihypertensive drug history was taken. Global 
disease activity was measured by the SLE disease 
activity index (SLEDAI)12 while the British Isles 
Lupus Assessment Group (BILAG)-2004 renal 
score was used to assess renal involvement13 and 
Systemic Lupus International Collaborating 
Clinics/American College of Rheumatology 
(SLICC/ ACR) Damage Index (SDI) was used to 
assess SLE related damage.14  
 
Laboratory Work: 
Routine laboratory investigations for LN 
patients: Complete blood count by Coulter Max 
MUG–HL–CCl and erythrocyte sedimentation rate 
(ESR) by Westergren method. Biochemical  
parameters measured included  serum creatinine, 
cholesterol, triglycerides, high density lipoproteins, 
and low density lipoproteins and  24-hours urine 
proteins and urine creatinine which were assayed by 
enzymatic procedures using Beckman Synchron 
CX7 Clinical System (Beckman Coulter Inc. 
California, USA), detection of  anti-double stranded  
DNA (anti-ds DNA) by ELISA (quanta lite  ds 
ELISA.www.nt-protons.com), and serum 
complement-3 (C3) using MININEPH TM 
(Binding Site Ltd Birmingham, UK). 
Detection of serum angiotensin II and AT1 
receptor CC genotype for patients and controls: 
Serum angiotensin II was measured by quantitative 
ELISA#(supplied by Wuhan Eiaab Science Co., 
Ltd"A1710 Guangguguoji, East Lake Hi-Tech 
Development Zone, Wuhan 430079, China). 
According to manufacturer’s instructions; a 
reference curve is used to ascertain the 
concentration of angiotensin II in unknown 
specimens by comparing the optical density (OD) 
of the samples to the standard curve. Detection 
Range is 31.2-2000 pg/mL. 
Detection of AT1A receptor genotype A1166C by 
PCR-restriction fragment length polymorphisms 
(PCR RFLP) using thermal cycler (PCR 
EXPRESS-HYBAID): 
- DNA was isolated from whole blood using Gentra 
Generation capture column kit according to the 
manufacturer’s instructions (13355 10th Avenue 
North, suite 120 Minneapolis, Minnesota 55441 
USA). 
- The extracted DNA was amplified in a 25 µl 
mixture tube consisting of 5 uL of DNA extract 
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(40ng DNA), 4.5 uL of RNase-Free water, 12.5 ul 
of the ready to use master mix supplied by 
QIAGEN 
(www.qiagen.com/goto/TechSupportCenter), and 
1.5uL of each of the forward primer '5-
AATGC'TTGTAGCCAAAGTCACCT-3' and 
reverse prime5’-GGCTTTGCTTTGTCTTGTTG- 
supplied by Midland certified reagent company 
(www.oligos.com/thioIModified.htm). 
- Thermo cycling consisted of an initial 
denaturation at 94°C for two minutes, then 40 
cycles of: denaturation at 94°C for one minute, 
annealing at 60°C for one minute, extension at 
72°C for two minutes. A final extension time of 
72°C for 10 minutes. The 1166 C allele contains 
an additional recognition site for the restriction 
endonuclease DdeI that is absent in the A 1166 
allele. Accordingly, PCR amplification products 
were digested at 37°Cwith DdeI supplied by NEW 
ENGLAND BioLabs (www.neb.com.) and 
electrically separated on a 2% agarose ethidium 
bromide gel supplied by Fermentas 
(www.fermentas.com).  
- According to the band length of restriction 
fragment, genotypes defined for AT1 receptor 
were homozygous AA genotype if the band length 
equal 546 bp (uncut), homozygous CC genotype if 
the band is divided into 2 parts: 435 bp and 111 
bp length and  heterozygous AC genotype if it 
yield 3bands 546,435 and 111 bp. 
 
Statistical methods:  
Statistical analysis was performed using Statistical 
Package for Social Sciences, Version 17.0 (SPSS, 
Inc., Chicago, III., USA) for Windows. Continuous 
variables were analyzed as mean values ± standard 
deviation (SD) or median (range) as appropriate. 
Rates and proportions were calculated for 
categorical data.  Kolmogorov-Smirnov test of 
normality was done to assess normality of 
continuous variables before starting the analysis 
especially in groups with small numbers. 
Differences among continuous variables with 
normal distribution were analyzed by Student’s T-
test. Mann-Whitney test for non-parametric 
quantitative data and Chi-square test for comparing 
categorical variables. Pearson’s Correlations and 
non-parametric analogue Spearman Rho were used. 
Receiver Operating Characteristic (ROC) Curve 
was designed which is a plotting of sensitivity 
versus 1-specificity at different cutoff values of the 
studied variable. P value of <0.05 was considered 
statistically significant and less than 0.001 was 
considered as highly significant.  
 
RESULTS 
The clinical and the laboratory data of the studied 
patients are shown in table 1:  
Inactive SLE was reported in 6 (24%) patients with 
SLEDAI = 0. Twelve (48%) patients had mild SLE 
activity (SLEDAI= 2– 4 with a median of 2) and 6 
(24%) had moderate lupus activity (SLEDAI = 6– 
10 with a median of 6).  
Assessment of LN using BILAG–renal score 
revealed that 15 (60%) patients had inactive LN 
with BILAG D score, 5 (20%) patients had mild LN 
activity with BILAG C score and 5 (20%) had 
moderate renal activity with BILAG B score.  
Lupus related damage as assessed by SDI was 
absent in 23 (92%) patients where SDI was zero. 
Only 2 (8%) patients had a SDI of 2. The first one 
was an 18-years old female with LN class III who 
experienced persistent pericardial effusion and 
pulmonary fibrosis. The other patient was a 12- 
years old female with LN class II who had cataract 
and pulmonary fibrosis.  
All (100%) patients were on steroid therapy at 
a dose of (0.1-0.5 mg/kg/day). Ten (40%) patients 
were on pulsed intravenous cyclophosphamide at a 
dose of (500-750 mg/m2/month) and 13 (52%) 
patients were on azathioprine at a dose of (1.5-3 
mg/kg/day).  
Serum Ang II and AT1 receptor   CC genotype 
among patients and controls:  
Patients had significantly higher serum Ang II than 
the controls (Z= -6.3, p=0.0001) (figure 1). The best 
cut-off value of serum Ang II was 155 pg/ml with 
100% sensitivity and 100 % specificity. So, levels 
above 155 pg/ml were considered abnormally high 
(figure 2). The frequency of AT1 receptor CC 
genotype was significantly higher (58.3%) among 
patients as compared to the control group (28.5%) 
(X2= 7.1, p=0.008) (figure 3).  
Variation of serum Ang II in relation to AT1 
receptor genotype:  
Patients with AT1 receptor CC genotype had 
comparable serum Ang II to those with wild AT1 
receptor (AA genotype) (table 3). 
Variation of Serum Ang II and AT1 receptor CC 
genotype in relation to the age and gender of the 
patients and controls:  
There was no significant correlation between serum 
Ang II and the age of the patients or controls 
(p>0.05). Similarly, serum Ang II was comparable 
among male and female patients and controls 
(p>0.05). No gender difference was observed in   
the frequency of AT 1 receptor CC genotype of 
patients and controls (p>0.05). 
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The relationship between serum Ang II and AT1 
receptor CC genotype and the age at onset of SLE:  
There was no significant correlation between serum 
Ang II and the age at onset of SLE (r= 0.007, 
p>0.05). Also, patients with AT1 receptor CC 
genotype had comparable age at onset of SLE to 
those with wild AT1 receptor (AA genotype) (Z=-
1.35, p>0.05). 
The variation with the histological class of LN:  
Serum Ang II and the frequency of AT1 receptor 
CC genotype were comparable in patients with 
proliferative LN (LN class III and IV) and those 
with LN class II (p>0.05).  
The effect of serum Ang II and AT1 receptor CC 
genotype on the blood pressure: 
Serum Ang II was comparable between 
hypertensive and normotensive LN patients (t=0.47, 
p=0.05). Also, the frequency of AT1 receptor CC 
genotype did not vary significantly between these 
patients (X2 =1.37, p>0.05).  
The relation to the studied laboratory indices:    
Serum Ang II did not correlate significantly with 
serum C3, ESR and anti-dsDNA as well as 
creatinine clearance, 24 hours urinary proteins and 
serum lipids (table 2).  Similarly, patients with AT1 
receptor CC genotype and those with wild AT1 
receptor (AA genotype) were comparable 
concerning the same laboratory markers (table 3).       
The effect on SLE activity and related damage: 
Serum Ang II did not correlate significantly with 
SLEDAI (r = 0.15, p>0.05), BILAG-renal score 
(r=-0.19, p>0.05), moreover, serum Ang II did not 
vary significantly between different grades of 
SLEDAI (F=0.22, p>0.05). Serum Ang II did not 
correlate significantly with SDI for lupus related 
damage (r=-0.02, p>0.05). Also, patients with AT1 
receptor CC genotype and those with wild AT1 
receptor (AA genotype) had comparable SLEDAI 
(Z=-0.27, p>0.05), BILAG-renal score (Z=0.51, 
p>0.05) and SDI (Z=-0.24, p>0.05). The frequency 
of AT1 receptor CC genotype was comparable 
among patients in remission and those with mild 
and moderate   SLEDAI (X2=0.68, p>0.05). 
The effect of the immunosuppressive therapy:  
Serum Ang II was not affected significantly with 
the types or the doses of the immunosuppressive 
therapy namely steroids (r=0.09, p>0.05), 
cyclophosphamide (r=-0.0006, p>0.05) and 
azathioprine (r=-0.09, p>0.05). Patients with AT1 
receptor genotype A1166C and those with wild 
AT1 receptor (AA genotype) received comparable 
doses of steroids (Z=-0.84, p>0.05), and 
azathioprine (Z=-0.5, p>0.05).  
 
Table 1. The clinical and the laboratory data of the studied patients. 
 
N=24 Mean (range ) SD Median (IQR) 
Age (years) 13.9 (5-18) 3.6 15 (3) 
Age at onset of SLE (years) 10.3 (3-16) 3.1 11(3.3) 
Duration (years ) 3.6 (1-12) 2.6 3(1.8) 
C3 (mg/dl) 103 (37-205) 41.4 96.7(168) 
Anti-ds DNA (IU/ml) 368.8 (45-1365) 360.8 200.5(565.5) 
ESR (mm/hr) 26.5 (5-75) 16.3 22(23.8) 
Serum creatinine (mg/dl) 0.5 (0.3-0.9) 0.15 0.45(0.18) 
Creatinine clearance (ml/ min / 1.73m2) 116.3 (22-323) 63.7 102(35.3) 
24 hours urinary proteins (gms) 0.36 (0-4) 0.81 0.1(0.2) 
Triglycerides (mg/dl) 147.8 (47-250) 61.5 157(107.3) 
Low density lipoproteins (mg/dl) 140.7 (45-250) 47 138(66.3) 
High density lipoproteins (mg/dl) 49.5 (10-150) 27.9 40(24.3) 
Cholesterol (mg/dl) 201 (115-259) 44.4 210(67.8) 
Serum Ang II (pg/ml) 307.5 (180-500) 81.6 300 (130) 
SLEDAI 3.1 (0-10) 2.8 2(5) 
BILAG-renal score 0.8 (0-3) 1.2 0(1) 
SDI 0.2 (0-2) 0.6 0 
Cumulative dose of steroids (gms) 16.3 (4.9-32.3) 8.7 13.5(16.2) 
Cumulative dose of cyclophosphamide (gms) 4.1 (1.5-10) 3.1 2.75(4.5) 
Cumulative dose of azathioprine (gms) 47.9 (8-94) 24.4 45.6(31) 
N: number, SD: Standard Deviation, IQR: interquartile range, SLE: Systemic lupus erythematosus, C3: 
complement-3, Anti-dsDNA: Anti-double stranded deoxyribonucleic acid, ESR: Erythrocyte 
sedimentation rate, hr: hour, Ang II: angiotensin II, SLEDAI: Systemic lupus erythematosus disease 
activity index, BILAG: British Isles Lupus Assessment Group, SDI: Systemic Lupus International 
Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index. 
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Table 2. The relation of the studied laboratory markers to serum Ang II 
 
LN patients 
n (%) = 24 (100%) 
Studied immunological markers  




C3  -0.2 0.33 
Anti-dsDNA  0.19 0.38 
ESR   0.25 0.24 
Serum creatinine  -0.54 0.22 
Creatinine clearance  0.3 0.15 
24hrs. Urinary proteins   0.2 0.3 
S. Chol   0.06 0.7 
S. TG    -0.11 0.6 
 HDL    -0.2 0.3 
 LDL  -0.16 0.4 
LN: Lupus nephritis, S.Ang II: serum angiotensin II, n: number, %: 
percentage, SD: standard deviation, C3: Complement 3, Anti-
dsDNA: Anti double stranded deoxyribonucliec acid, ESR: 
erythrocyte sedimentation rate, hrs: hours, S: Serum, Chol: 
Cholesterol, TG: Triglyceride, HDL: High density lipoprotein, LDL: 
Low density lipoprotein, P>0.05: non-significant. 
 
 
Table 3. Variation of the studied laboratory markers in relation to AT1 receptor genotype A1166C 
 
 AT1 receptor gene 
 (A allele) 
n (%): 10 (41.7%) 
AT1 receptor gene  
(C allele) 
n (%): 14 (58.3%) 
test P 
Serum Ang II (pg/ml) 
Mean (SD) 
282(72.5) 325.7 (85.2) 1.3 0.2 
C3 (mg/dl) 
Median (range) 
105.7 (55-205) 83.5 (37-152) Z=-1.1 0.25 
Anti-dsDNA (IU/ml) 
Median (range) 
600 (90-882) 200 ( 45-1365) Z= -1.3 0.2 
ESR 
Median (range) 
20 (5-40) 24 (8-75) Z=- 1.1 0.3 
Serum creatinine (mg/dl) 




105 (22-273) 101 (72-323) Z=  - 0.3 0.7 
24hrs. Urinary proteins (g/24h) 
Median (range) 
0.1 (0-1) 0.1 (0.05-4) Z= -1.7 0.1 
S. Chol (mg/dl) 
Mean± SD 
203 ± 43.4 200 ± 46.7 t = - 0.2 0.85 
S. TG (mg/dl) 
Mean± SD 
152 ± 69.4 145 ± 57.8 t = - 0.3 0.8 
HDL (mg/dl) 
Median (range) 
47 (35-150) 40 (10-85) Z= -1.1 0.3 
LDL (mg/dl) 
Median (range) 
139 (45-200) 138 (70-250) Z= - 0.23 0.8 
AT1A: Angiotensin II type 1A, n: number, %: percentage, SD: standard deviation, C3: Complement 3, Anti-dsDNA: 
Anti double stranded deoxyribonucliec acid, ESR: erythrocyte sedimentation rate, hrs: hours, S: Serum, Chol: 
Cholesterol, TG: Triglyceride, HDL: High density lipoprotein, LDL: Low density lipoprotein, P >0.05: non-significant. 
 
 




Figure 1. Serum angiotensin II in the studied patients and the 
control group. 
Ang II: angiotensin II. 
Boxes enclose the interquartile ranges (IQR) (the 25th and 75th 
percentiles). The horizontal line inside the box represents the 
median (50th) and whiskers represent maximum and minimum 
values (Range). The closed small circles and stars represent 







Figure 2. Receiver Operating Characteristic (ROC) curve to define the best cutoff value of serum angiotensin 
II to differentiate between the studied patients and the control group. 
 
It was found that  the best cut-off value of serum Ang II was 155 pg/ml with both sensitivity and specificity of 
100 %. So, levels above 155 pg/ml were considered abnormally high. 




Figure 3. The frequency of AT1 receptor CC genotype in patients and controls. 
 
DISCUSSION 
The inflammatory role of Ang II and the effect of 
AT1 receptor polymorphism A1166C (CC 
genotype) in the pathogenesis of SLE and 
particularly LN is still unclear. Furthermore, their 
effect on the clinical phenotype of LN is rather 
undefined. In this study, the significantly increased  
serum Ang II and the frequency of AT1 receptor 
CC genotype among patients supports the 
inflammatory role of Ang II  in SLE and may 
indicate that AT1 receptor CC genotype  has a 
pathogenic effect rather than a normal variation. 
However, this needs to be verified on a wider scale. 
Previous studies investigated the role of ACE 
activity in SLE and RAS activation has been 
reported in SLE patients.2,3,15 ACE catalyses the 
formation of Ang II from its inactive precursor,  
Ang I.16 It has been  reported that AT1  receptor CC 
genotype   was more frequent in adult SLE patients 
as compared to healthy controls. This might 
increase the susceptibility to SLE, however the 
susceptibility to SLE, its nephropathy and 
progression to renal failure was only performed by 
studying the genetic polymorphism of ACE which 
showed controversial results.17 In this series, AT1 
receptor CC genotype did not affect serum 
angiotensin, this implies that the polymorphism 
might not affect the sensitivity of the receptor or 
have significant feedback on serum Ang II.  
The presence of AT1 receptor CC genotype did 
not affect significantly the age at onset of SLE and 
this has been previously reported.17 SLE is a 
complex disease with the interplay of multiple 
factors resulting in different lupus presentations.  
Also, we did not find a specific gender predilection 
for AT1 receptor CC genotype. This has been 
reported in an earlier study.18 The lack of significant 
effect of age and sex on serum Ang II in both 
patients and controls suggests that it is rather 
regulated by hemodynamic factors as well as the 
inflammatory milieu.  
In this series, LN class III and IV were not 
associated with significantly higher serum Ang II or 
frequency of AT1 receptor CC genotype. The 
limited number of patients in each class of LN 
would not allow for making solid conclusions as to 
the role of AT1 receptor CC genotype and serum 
Ang II in the pathogenesis and progression of LN.   
Other investigators also reported that there was 
no significant correlation between AT 1 receptor 
CC genotype and LN classes.17,19 It has been 
suggested that  the influence of this polymorphism  
on SLE may be related to the interaction of the 
genotype variables of the different components in 
the RAS system.17,20,21  
Ang II is an important contributor to blood 
pressure regulation and plays a significant role in 
hypertension and in the pathophysiology of 
vascular damage during the course of 
hypertension.22 However, in this study, there was no 
significant association between serum Ang II or the 
frequency of AT1 receptor CC genotype and 
hypertension demonstrating the multifactorial 
nature of hypertension in these patients including 
the use of long term steroids therapy and 
hyperlipidemia.  A previous study reported that this 
polymorphism had no significant effect on the 
development of hypertension in adult SLE 
patients,17 whereas, several  other studies reported 
that reported that AT1 receptor  CC genotype   had 
a significant role in the development of essential 
hypertension.18,23-25 
Chi square = 7.06, 
p = 0.008 
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In the present study, we failed to demonstrate a 
significant association between serum Ang II and  
AT1 receptor CC genotype and indices of lupus 
activity whether SLEDAI, serum anti-dsDNA titre  
or complement-3. The fact that the  majority of 
patients had mild activity or were in remission 
(72%) could explain this result  especially that 
patients with moderate and high lupus activity had 
higher serum Ang II, albeit insignificant, compared  
to those with low grade activity or in remission.  
Interestingly, serum Ang II and the frequency 
of AT1 receptor CC genotype did not vary with 
BILAG-renal score as well as renal function tests. 
Intra-renal Ang II may better correlate with LN and 
its presentation as it has been reported that renal 
tubules and interstitial compartments contain 
significantly high levels (1000-fold) of Ang II 
compared with the plasma level.7 Intra-renal Ang II 
contributes to the recruitment of inflammatory cells 
into the kidney and the adhesion of circulating cells 
to endothelial and mesangial cells.8 Furthermore, 
sustained elevation of intra-renal Ang II induces 
proteinuria accompanied by progressive injury of 
the glomerular filtration barrier.26-28  
A previous study found that there was no 
significant difference between patients with AT1 
receptor CC genotype and those with AA genotype 
as regards SLEDAI and BILAG-renal score.17    
There are reports that AT1 receptor CC genotype   
was associated with the progression of chronic 
kidney diseases to end stage renal failure.29,30 To the 
best of the authors knowledge, there are no 
previously published  studies concerning serum 
Ang II in LN. 
In this study, serum Ang II and AT1 receptor 
CC genotype did not affect significantly lupus 
related damage. This finding could be explained by 
the lack of significant effect of serum Ang II on 
lupus activity in terms of SLEDAI and BILAG-
renal score which are eventually reflected as lupus 
related damage.  
Lack of significant association between serum 
Ang II and AT1 receptor CC genotype and serum 
lipids needs to be verified on a wider scale. Ang II 
may provide a link between atherosclerotic risk 
factors such as hypercholesterolemia and 
hypertension, since high cholesterol levels have 
recently been shown to increase angiotensinogen 
and Ang II.31 However, a previous study reported 
that AT1 receptor genotype A1166C had no effect 
on serum lipids.32  
In conclusion, serum Ang II and AT1 receptor 
CC genotype seem to have pathogenic role in LN 
being significantly higher among patients than the 
healthy subjects.  However, elevated serum Ang II 
and AT1 receptor CC genotype did not show a 
significant effect on the histological and clinical 
consequences of LN.  Further studies on a wider 
scale are needed to evaluate serum Ang II and AT1 
receptor CC genotype  linking them  to the intra-
renal  Ang II  for a better understanding of their  
role in the etiopathogenesis of  LN   and to define  




1. Prkacin I, Novak B, Sertic J, Mrzljak A. 
Angiotensin-converting enzyme gene polymorphism 
in patients with systemic lupus. Acta Med Croatica 
2001; 55:73–6. 
2. Rabbani MA, Mahmood MS, Mekan SF, Frossard 
PM. Association of angiotensin-converting enzyme 
gene dimorphisms with severity of lupus disease. 
Saudi J Kidney Dis Transplant 2008; 19 (5):761-6. 
3. Klahr S, Morrissey JJ. The role of vasoactive 
compounds, growth factors and cytokines in the 
progression of renal disease.  Kidney Int 2000; 57 
(75): S7–S14. 
4. Smith W, Morgan P. Actions of angiotensin II on 
the heart. Cited at http://www.uptodate.com. Last 
updated on June 18th 2012. Accessed on September 
18th 2012. 
5. De Gasparo M, Catt KJ, Inagami T, Wright JW, 
Unger T. "International union of pharmacology. 
XXIII. The angiotensin II receptors". Pharmacol Rev 
2000; 52 (3): 415–72. 
6. Mehta PK, Griendling KK. Angiotensin II cell 
signaling: physiological and pathological effects in 
the cardiovascular system. Am J Physiol Cell Physiol 
2007; 292: C82–97. 
7. Esteban V, Ruiz-Ortega M, Rodríguez-Vita J, 
Sánchez-López E, Carvajal G, Egido J. 
Angiotensin II: a key factor in the inflammatory and 
fibrotic response in kidney diseases. Nephrol Dial 
Transplant 2006; 21: 16–20. 
8. Crowley SD, Vasievich MP, Ruiz P, Gould SK, 
Parsons KK, Pazmino AK, et al. Glomerular 
type 1 angiotensin receptors augment kidney injury 
and inflammation in murine autoimmune nephritis. J 
Clin Invest 2009; 119: 943-53. 
9. Hochberg MC. Updating the American College of 
Rheumatology revised criteria for the classification of 
systemic lupus erythematosus. Arthritis Rheum 1997; 
40: 1725. 
10. Weening JJ, D’Agati VD, Schwartz MM, Seshan 
SV, Alpers CE, Appel GB, et al. The classification 
of glomerulonephritis in systemic lupus 
erythematosus revisited. Kidney Int 2004; 65: 521–
30. 
Serum Angiotensin II and receptor polymorphism in lupus nephritis 
 35 
11. National Heart, Lung, and Blood Institute. Report of 
the Second Task Force on Blood Pressure Control in 
Children-1987. Pediatrics 1987;79:1. 
12. Bombardier C, Gladman DD, Urowitz MB, Caron 
D, Chang CH. Derivation of the SLEDAI. A disease 
activity index for lupus patients. The Committee on 
Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 
630-40. 
13. Isenberg DA, Rahman A, Allen E, Farewell V, 
Akil M, Bruce IN, et al. BILAG 2004. 
Development and initial validation of an updated 
version of the British Isles Lupus Assessment 
Group's disease activity index for patients with 
systemic lupus erythematosus. Rheumatology 2005; 
44: 902-6. 
14. Gladman D, Ginzler E, Goldsmith C, Fortin P, 
Liang M, Urowitz M, et al. The development and 
initial validation of the Systemic Lupus International 
Collaborating Clinics/American College of 
Rheumatology damage index for systemic lupus 
erythematosus. Arthritis Rheum 1996; 39: 363-9. 
15. Abbas D, Ezzat Y, Hamdy E, Gamil M. 
Angiotensin-converting enzyme (ACE) serum levels 
and gene polymorphism in Egyptian patients with 
systemic lupus erythematosus. Lupus 2011; 21: 103-
10. 
16. Wharton J, Walsh DA, Catravas J. Angiotensin 
converting enzyme in human synovium: increased 
stromal [125I] 351A binding in rheumatoid arthritis. 
Ann Rheum Dis 2000; 59:125–31. 
17. Sprovieri SR, Sens YA. Polymorphisms of the 
renin-angiotensin system genes in Brazilian patients 
with lupus nephropathy. Lupus 2005; 14: 356-62. 
18. Bonnardeaux A, Davies E, Jeunemaitre X, Féry 
I, Charru A, Clauser E, et al. Angiotensin II type 
1 receptor gene polymorphisms in human essential 
hypertension. Hypertension 1994; 24: 63–9. 
19. Sprovieri SR, Sens YA, Martini Filho D. 
Association between polymorphisms of the renin-
angiotensin system and more severe histological 
forms of lupus nephritis. Clin Nephrol 2005; 64: 20-
7. 
20. Pei Y, Scholey J, Thai K, Suzuki M, Cattran D. 
Association of angiotensinogen gene T235 variant 
with progression of immunoglobulin A nephropathy 
in Caucasian patients. J Clin Invest 1997; 100: 814-
20. 
21. Marre M, Jeunemaitre X, Gallois Y, Rodier M, 
Chatellier G, Sert C, et al. Contribution of 
genetic polymorphism in the renin-angiotensin 
system to the development of renal complications in 
insulin-dependent diabetes: Genetique de la 
Nephropathie Diabetique (GENEDIAB) study group. 
J Clin Invest 1997; 99: 1585-95. 
22. Fyhrquist F, Metsärinne K, Tikkanen I. Role of 
angiotensin II in blood pressure regulation and in the 
pathophysiology of cardiovascular disorders. J Hum 
Hypertens 1995; 9 (Suppl 5): S19-24.  
23. Wang WY, Zee RYL, Morris BJ. Association of 
angiotensin II type 1 receptor gene polymorphism 
with essential hypertension. Clin Genet 1997; 51:31–
4. 
24. Szombathy T, Szalai C, Katalin B, Palicz T, 
Romics L, Csaszar A. Association of angiotensin II 
type 1 receptor polymorphism with resistant essential 
hypertension. Clin Chim Acta 1998; 269: 91–100. 
25. Kainulainen K, Perola M, Terwilliger J, Kaprio 
J, Koskenvuo M, Syvänen A-C, et al. Evidence 
for the involvement of the type 1 angiotensin II 
receptor locus in essential hypertension. 
Hypertension 1999; 33:844–9. 
26. Kobori H, Harrison-Bernard LM, Navar LG. 
Urinary excretion of angiotensinogen reflects 
intrarenal angiotensinogen production. Kidney Int 
2002; 61:579–85. 
27. Miller PL, Rennke HG, Meyer TW. Glomerular 
hypertrophy accelerates hypertensive glomerular 
injury in rats. Am J Physiol 1991; 261:459-65. 
28. Hoffmann S, Podlich D, Hahnel B, Kriz W, 
Gretz N. Angiotensin II type 1 receptor 
overexpression in podocytes induces 
glomerulosclerosis in transgenic rats. J Am Soc 
Nephrol  2004; 15:1475-87. 
29. Whaley-Connell A, Chowdhury N, Hayden MR, 
Stump CS, Habibi J, Wiedmeyer CE, et al. 
Oxidative stress and glomerular filtration barrier 
injury: role of the renin-angiotensin system in the 
Ren2 transgenic rat. Am J Physiol 2006; 291: 1308-
14. 
30. Buraczynska M, Ksiazek P, Drop A, Zaluska W, 
Spasiewicz D, Ksiazek A. Genetic polymorphisms 
of the renin-angiotensin system in end-stage renal 
disease. Nephrol Dial Transplant 2006; 21 (4):979-
83. 
31. Elshamaa MF, Sabry SM, Bazaraa HM, Koura 
HM, Elghoroury EA, Kantoush NA, et al. 
Genetic polymorphism of ACE and the angiotensin II 
type1 receptor genes in children with chronic kidney 
disease J Inflamm 2011; 8: 20. 
32. Daugherty A, Rateri DL, Lu H, Inagami T, 
Cassis LA. Hypercholesterolemia stimulates 
angiotensin peptide synthesis and contributes to 
atherosclerosis through the AT1A receptor. 
Circulation 2004; 110: 3849–57. 
